Cytovance Biologics is launching dedicated business development activities in international markets for biologic contract manufacturing of therapeutic proteins and monoclonal antibodies. Molly S. McGlaughlin MeD, has been appointed to the newly created position of vice president of Sales & Business Development – International, and will be spearheading this critical strategic growth initiative. Ms. McGlaughlin joined Cytovance in 2008 as vice president of Sales & Business Development; she and her team were responsible for the robust revenue growth through securing custom-designed development and manufacturing agreements with numerous clients.

William Dull has been appointed vice president of Sales & Business Development – North America, and will be responsible for Cytovance’s business development activities in that region, including the marketing and sales. Mr. Dull comes to Cytovance with more than 24 years of successful experience in the biotech and pharmaceutical industry, in particular U.S. and worldwide marketing and sales, medical affairs and strategic and commercial planning. Mr. Dull has held senior positions of increasing responsibility at ARCA biopharma, Scios, Transkaryotic Therapies (TKT) now Shire Human Genetic Therapies (HGT), Bio-Technology General now Savient Pharmaceuticals and Genentech.

Darren Head, president and chief executive officer of Cytovance, commented, “Molly’s successful track record will be a valuable asset as we promote our services in emerging markets and William’s cross-functional business background adds great depth to our leadership team. The complete Cytovance team recognizes our facility and personnel expansion as an integral element to our business model and a testament to our commitment to meet the science and outsourcing manufacturing requirements of our global customers.”